Patterns and outcome of unplanned care in lung cancer patients: an observational study in a medical oncology department.

Lung cancer cancer emergencies cancer management quality of care unplanned care

Journal

Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875

Informations de publication

Date de publication:
30 Aug 2023
Historique:
received: 27 01 2023
accepted: 04 07 2023
medline: 11 9 2023
pubmed: 11 9 2023
entrez: 11 9 2023
Statut: ppublish

Résumé

There is increasing interest in unplanned care utilization among lung cancer patients and its evaluation should allow the identification of areas for quality improvement. Being a major priority for transformation in oncology, we aim to measure the risk and burden of unplanned care in a medical oncology department and identify factors that determine acute care. This was an observational retrospective cohort study that included all lung cancer patients treated at Puerta de Hierro-Majadahonda University Hospital between January 1st 2016 and December 31st 2020. Data cut off: June 30th, 2021. The main objective was to assess the incidence of unplanned care, emergency department (ED) visits and unplanned hospital admissions, from the first visit to the medical oncology service and its potential conditioning variables, considering patient death as a competitive event. As secondary objectives, a description and a quality of unplanned care evaluation was carried out. A total of 821 lung cancer patients, all histologies and stages, were included (median follow-up: 32.8 months). Six hundred and eighty-one patients required consultation in the ED (82.9%), and 558 required an unplanned admission (68%). Eighty-six percent of ED consultations and 80.9% of unplanned hospital admissions were related to cancer or its treatment. The 1-year cumulative incidence for ED consultation and for unplanned hospital admission was 71.3% (95% CI: 67.8-74.5%) and 56.7% (95% CI: 53-60%), respectively. In the multivariable analysis, a higher tumor stage increased the risk of consultation in the ED, while a higher stage, Eastern Cooperative Oncology Group performance status (ECOG PS) 2 compared to ECOG PS 0, male sex, opioid or steroid use at first consultation increased the risk of unplanned admission. Our study shows that lung cancer patients have an extremely high demand for unplanned care. It is an early need and related to cancer in the majority of consultations and admissions and therefore a key issue for the management of oncology departments. We must optimize the follow-up of patients with a higher risk of unplanned care, advanced lung cancer or symptomatic patients, incorporating remote monitoring strategies and early interventions, as developing specific urgent care pathways for a better comprehensive cancer care.

Sections du résumé

Background UNASSIGNED
There is increasing interest in unplanned care utilization among lung cancer patients and its evaluation should allow the identification of areas for quality improvement. Being a major priority for transformation in oncology, we aim to measure the risk and burden of unplanned care in a medical oncology department and identify factors that determine acute care.
Methods UNASSIGNED
This was an observational retrospective cohort study that included all lung cancer patients treated at Puerta de Hierro-Majadahonda University Hospital between January 1st 2016 and December 31st 2020. Data cut off: June 30th, 2021. The main objective was to assess the incidence of unplanned care, emergency department (ED) visits and unplanned hospital admissions, from the first visit to the medical oncology service and its potential conditioning variables, considering patient death as a competitive event. As secondary objectives, a description and a quality of unplanned care evaluation was carried out.
Results UNASSIGNED
A total of 821 lung cancer patients, all histologies and stages, were included (median follow-up: 32.8 months). Six hundred and eighty-one patients required consultation in the ED (82.9%), and 558 required an unplanned admission (68%). Eighty-six percent of ED consultations and 80.9% of unplanned hospital admissions were related to cancer or its treatment. The 1-year cumulative incidence for ED consultation and for unplanned hospital admission was 71.3% (95% CI: 67.8-74.5%) and 56.7% (95% CI: 53-60%), respectively. In the multivariable analysis, a higher tumor stage increased the risk of consultation in the ED, while a higher stage, Eastern Cooperative Oncology Group performance status (ECOG PS) 2 compared to ECOG PS 0, male sex, opioid or steroid use at first consultation increased the risk of unplanned admission.
Conclusions UNASSIGNED
Our study shows that lung cancer patients have an extremely high demand for unplanned care. It is an early need and related to cancer in the majority of consultations and admissions and therefore a key issue for the management of oncology departments. We must optimize the follow-up of patients with a higher risk of unplanned care, advanced lung cancer or symptomatic patients, incorporating remote monitoring strategies and early interventions, as developing specific urgent care pathways for a better comprehensive cancer care.

Identifiants

pubmed: 37691863
doi: 10.21037/tlcr-23-48
pii: tlcr-12-08-1752
pmc: PMC10483072
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1752-1765

Informations de copyright

2023 Translational Lung Cancer Research. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-48/coif). MP serves as an unpaid editorial board member of Translational Lung Cancer Research from October 2021 to September 2023. The other authors have no conflicts of interest to declare.

Références

J Cancer Res Clin Oncol. 2020 May;146(5):1169-1196
pubmed: 32246217
JCO Oncol Pract. 2021 Oct;17(10):e1567-e1575
pubmed: 33961497
Nat Rev Clin Oncol. 2019 May;16(5):312-325
pubmed: 30700859
BMJ Open. 2019 May 28;9(5):e026471
pubmed: 31142524
Health Aff (Millwood). 2014 Oct;33(10):1793-800
pubmed: 25288424
Support Care Cancer. 2021 Jul;29(7):4159-4164
pubmed: 33404804
J Oncol Pract. 2016 Oct;12(10):e924-e932
pubmed: 27858564
Eur Respir J. 2015 Apr;45(4):867-8
pubmed: 25829427
Pract Radiat Oncol. 2015 May-Jun;5(3):e245-e253
pubmed: 25413398
Support Care Cancer. 2016 Jul;24(7):2827-35
pubmed: 26816091
Emerg Cancer Care. 2022;1(1):4
pubmed: 35844668
J Clin Oncol. 2017 Nov 1;35(31):3610-3617
pubmed: 28850290
JCO Clin Cancer Inform. 2019 Apr;3:1-10
pubmed: 30995122
Clin Transl Oncol. 2019 Nov;21(11):1472-1481
pubmed: 30864021
Cancer Invest. 2022 Aug;40(7):567-576
pubmed: 35671042
JAMA Oncol. 2017 Oct 12;3(10):e172450
pubmed: 28859189
J Clin Med. 2020 May 17;9(5):
pubmed: 32429507
JAMA Surg. 2021 Aug 1;156(8):740-746
pubmed: 34076691
J Oncol Pract. 2019 Jan;15(1):e20-e29
pubmed: 30523749
J Clin Oncol. 2021 Aug 10;39(23):2586-2593
pubmed: 33999660
Stat Med. 2017 Nov 30;36(27):4391-4400
pubmed: 28913837
J Oncol Pract. 2016 May;12(5):e594-602
pubmed: 27048613
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Oncol Pract. 2019 Jun;15(6):e490-e500
pubmed: 30964735
BMJ Open. 2022 Apr 5;12(4):e057693
pubmed: 35383081
J Community Support Oncol. 2017 Mar-Apr;15(2):95-102
pubmed: 33215043
JCO Oncol Pract. 2022 Jan;18(1):e129-e136
pubmed: 34383579
BMC Palliat Care. 2021 Jan 26;20(1):24
pubmed: 33499835
Cancer Res Treat. 2022 Jul;54(3):680-689
pubmed: 34583460
Support Care Cancer. 2016 Mar;24(3):1251-60
pubmed: 26306522
South Med J. 2012 Aug;105(8):418-23
pubmed: 22864099
JAMA Netw Open. 2022 Mar 01;5(3):e221078
pubmed: 35244701
JAMA. 2014 Nov 12;312(18):1888-96
pubmed: 25387186
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Am J Emerg Med. 2018 Nov;36(11):2038-2043
pubmed: 29573899
Eur J Cancer Care (Engl). 2021 Mar;30(2):e13361
pubmed: 33216423
JAMA Oncol. 2015 Dec;1(9):1333-9
pubmed: 26378774
BMC Health Serv Res. 2019 Sep 6;19(1):647
pubmed: 31492185
Eur J Cancer Care (Engl). 2019 Jan;28(1):e12909
pubmed: 30238542
J Oncol Pract. 2018 May;14(5):306-313
pubmed: 29664697
Lancet Oncol. 2013 Nov;14(12):1165-74
pubmed: 24131614

Auteurs

Juan C Sánchez (JC)

Medical Oncology Department, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain.

Beatriz Nuñez-García (B)

Medical Oncology Department, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain.

Alberto Ruano-Ravina (A)

Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.
Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
CIBER de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain.

Mariola Blanco (M)

Medical Oncology Department, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain.

Arturo Ramos Martín-Vegue (AR)

Admission and Clinical Documentation Department, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain.

Ana Royuela (A)

Biostatistics Unit, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERESP, ISCIII, Madrid, España.

Blanca Cantos (B)

Medical Oncology Department, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain.

Miriam Méndez (M)

Medical Oncology Department, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain.

Virginia Calvo (V)

Medical Oncology Department, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain.

Mariano Provencio (M)

Medical Oncology Department, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain.
Biomedical Sciences Research Institute, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain.

Classifications MeSH